OncoAlert and ecancer ASCO roundup - Day 3

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

OncoAlert and ecancer weekly roundup for January 25 - 31, 2021

Advances and challenges in treating melanoma and breast cancer in Romania

OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML

Updates in geriatric medical oncology from SIOG meeting

Priorities of cancer research in Nepal

Treating ALL patients during the COVID-19 pandemic